CompletedEarly Phase 1

Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

United States150 participantsStarted 2023-06-23

Plain-language summary

The aim of this project is to investigate the effects of riboflavin, also known as vitamin B2, on preventing delayed onset muscle soreness (DOMS) in ultramarathon athletes through a randomized placebo-controlled study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Male or female, aged 18 or over
✓. In good general health as evidenced by readiness to participate in an ultramarathon
✓. Ability to take oral medication and be willing to adhere to the study regimen
✓. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening.

Exclusion criteria

✕. Unable to read or understand English
✕. Under 18 years of age
✕. Pregnancy or lactation
✕. Known allergic reactions to components of the investigational drugs

What they're measuring

Muscle soreness measure for long stage of the ultramarathon

Timeframe: Baseline to 6 days

Trial details

NCT IDNCT05907850

SponsorSteven Moore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-30

View on ClinicalTrials.gov More Muscle Soreness trials